Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Qlife Holding

1.95 SEK

-2.02 %

Less than 1K followers

QLIFE

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.02 %
-31.51 %
-18.96 %
-6.94 %
-49.61 %
-30.41 %
-99.79 %
-99.98 %
-99.92 %

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.

Read more
Market cap
30.5M SEK
Turnover
356.97K SEK
Revenue
90K
EBIT %
-61,500 %
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Latest research

Latest analysis report

Released: 2023-12-07

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/2
2026

Annual report '25

26/2
2026

Extraordinary general meeting '26

13/5
2026

Interim report Q1'26

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release1/26/2026, 9:56 AM

Notice of Extraordinary General Meeting 2026 in Qlife Holding AB

Qlife Holding
Regulatory press release1/26/2026, 9:56 AM

Kallelse till extra bolagsstämma 2026 i Qlife Holding AB

Qlife Holding
Regulatory press release1/26/2026, 7:30 AM

Qlife Holding AB: Qlife submits Egoo PHE home testing system for regulatory approval

Qlife Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release1/26/2026, 7:30 AM

Qlife Holding AB: Qlife submits Egoo PHE home testing system for regulatory approval

Qlife Holding
Regulatory press release1/22/2026, 7:50 PM

Qlife Holding AB: Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

Qlife Holding
Regulatory press release1/22/2026, 7:50 PM

Qlife Holding AB: Qlife resolves on a partially guaranteed rights issue of approx. SEK 31.4 million and proposes an over-allotment option, enters bridge loan agreements and postpones the exercise period of warrants TO7

Qlife Holding
Press release1/19/2026, 7:30 AM

Qlife Holding AB: Qlife prepares for pharmacy testing in Nordic markets

Qlife Holding
Press release1/19/2026, 7:30 AM

Qlife Holding AB: Qlife prepares for pharmacy testing in Nordic markets

Qlife Holding
Press release1/15/2026, 7:30 AM

Qlife Holding AB: Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships

Qlife Holding
Press release1/15/2026, 7:30 AM

Qlife Holding AB: Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships

Qlife Holding
Press release12/23/2025, 7:30 AM

Qlife Holding AB: Qlife provides end-year operational update on key issues

Qlife Holding
Press release12/23/2025, 7:30 AM

Qlife Holding AB: Qlife provides end-year operational update on key issues

Qlife Holding
Regulatory press release12/16/2025, 7:31 AM

Qlife Holding AB: Qlife and Hipro sign exclusive commercial agreement covering Qlife's sale of Hipro products in EU and US markets

Qlife Holding
Regulatory press release12/16/2025, 7:31 AM

Qlife Holding AB: Qlife and Hipro sign exclusive commercial agreement covering Qlife's sale of Hipro products in EU and US markets

Qlife Holding
Regulatory press release12/16/2025, 7:30 AM

Qlife Holding AB: The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established

Qlife Holding
Regulatory press release12/16/2025, 7:30 AM

Qlife Holding AB: The Letter of Intent with Hipro Biotechnology regarding the reverse takeover has been extended until 31 December 2026 and the valuation term will re-evaluated once a structure has been established

Qlife Holding
Press release12/12/2025, 7:30 AM

Qlife Holding AB: Egoo Health powers AI-driven personalized diabetes management in China

Qlife Holding
Press release12/12/2025, 7:30 AM

Qlife Holding AB: Egoo Health powers AI-driven personalized diabetes management in China

Qlife Holding
Regulatory press release12/5/2025, 10:13 AM

Qlife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch

Qlife Holding
Regulatory press release12/5/2025, 10:13 AM

Qlife Holding AB: Qlife's Birmingham PKU clinical trial published with strong results - key milestone toward CE-mark submission and market launch

Qlife Holding
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.